Advertisement
Advertisement
STVN
Stevanato Group S.p.A.
17.85
USDSponsored
+0.10
+0.56%
May 21, 16:00 UTC -4
Closed
After-Market
17.86
+0.01
+0.08%
STVN Earnings Reports
Positive Surprise Ratio
STVN beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$305.04M
/$0.12
Implied change from Q1 26 (Revenue/ EPS)
+11.49%
/+9.09%
Implied change from Q2 25 (Revenue/ EPS)
+8.94%
/+9.09%
Stevanato Group S.p.A. earnings per share and revenue
On May 07, 2026, STVN reported earnings of 0.11 USD per share (EPS) for Q1 26, beating the estimate of 0.10 USD, resulting in a 5.06% surprise. Revenue reached 273.60 million, compared to an expected 274.74 million, with a -0.41% difference. The market reacted with a -5.11% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of 0.12 USD, with revenue projected to reach 305.04 million USD, implying an increase of 9.09% EPS, and increase of 11.49% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
What were Stevanato Group S.p.A.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Stevanato Group S.p.A. reported EPS of $0.11, beating estimates by 5.06%, and revenue of $273.60M, -0.41% below expectations.
How did the market react to Stevanato Group S.p.A.'s Q1 2026 earnings?
The stock price moved down -5.11%, changed from $19.00 before the earnings release to $18.03 the day after.
When is Stevanato Group S.p.A. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Stevanato Group S.p.A.'s next earnings report?
Based on 10
analysts, Stevanato Group S.p.A. is expected to report EPS of $0.12 and revenue of $305.04M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement